Novo Nordisk to Lower Drug Prices in U.S. Starting 2026

Novo Nordisk ( (NVO) ) has issued an update.

On November 6, 2025, Novo Nordisk announced an agreement with the U.S. Administration to reduce the prices of its semaglutide medicines, including Wegovy® and Ozempic®, starting in 2026. This initiative aims to expand access to these obesity treatments through U.S. Medicare Part D and Medicaid, as well as direct-to-patient cash channels. The agreement includes a pilot program for Medicare Part D coverage, expected to cover a majority of beneficiaries, and a three-year tariff exemption for Novo Nordisk. The company anticipates a low single-digit negative impact on its global sales growth in 2026 due to these changes.

The most recent analyst rating on (NVO) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.

Novo Nordisk’s overall stock score reflects strong financial performance and attractive valuation, offset by bearish technical indicators and challenges highlighted in the earnings call. The company’s strategic initiatives and robust growth in obesity care are positive, but market share loss and restructuring efforts present near-term risks.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, particularly diabetes, through scientific breakthroughs and expanding access to medicines. The company employs about 78,500 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.

Average Trading Volume: 15,207,517

Technical Sentiment Signal: Sell

Current Market Cap: $206.6B

See more data about NVO stock on TipRanks’ Stock Analysis page.